Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27921582 | 0.81 | KDM4E (0.53) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL19222365 | 0.80 | KDM4E (0.52) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL23488101 | 0.80 | KDM4E (1.00) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL17694678 | 0.78 | KDM4E (0.78) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL15558115 | 0.76 | KDM4E (0.61) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL14777184 | 0.74 | NPC1 (0.54) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL12419636 | 0.74 | TSHR (0.68) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL23488102 | 0.73 | KDM4E (0.80) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL203875 | 0.73 | KDM4E (0.52) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL1668031 | 0.73 | KDM4E (0.62) | KDM4ENPC1SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108031-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2016-04-21 | — | — | US | claimed |
| EP-2991963-A2 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | Heinrich-Heine-Universität Düsseldorf (DE) | 2016-03-09 | — | — | EP | claimed |
| WO-2014177464-A2 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2014-11-06 | — | — | WO | claimed |
| EP-2991963-B1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2021-07-07 | — | — | EP | disclosed |
| EP-2991963-B1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-20210147415-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147415-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20160108031-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108031-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-2991963-A2 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | Heinrich-Heine-Universität Düsseldorf (DE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014177464-A2 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177464-A2 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108031-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | RUNX1, ETV6, NPM1 | KDM4E 2323/4885NPC1 1916/4885SMN1; SMN2 4526/4885 |
| US-20210147415-A1 | INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION | RUNX1, ETV6, NPM1 | KDM4E 2323/4885NPC1 1916/4885SMN1; SMN2 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.